Adherence junction proteins in angiogenesis: Modulation by aspirin and salicylic acid

Journal of Cardiovascular Medicine

Volumn 13, Issue 3, 2012, Pages 187-193

  Khaidakov, Magomed ^b   Mitra, Sona ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

Adherens junctions; Angiogenesis; Aspirin; Endothelium; Salicylic acid

Indexed keywords

ACETYLSALICYLIC ACID; ADHERENS JUNCTION PROTEIN; BETA CATENIN; CATENIN; CYCLOOXYGENASE 2; MEMBRANE PROTEIN; P120 CATENIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P47PHOX SUBUNIT; SALICYLIC ACID; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CADHERIN; DELTA CATENIN; LEUKOCYTE ANTIGEN; NEUTROPHIL CYTOSOLIC FACTOR 1; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SALICYLIC ACID DERIVATIVE; VASCULOTROPIN A;

ADHERENS JUNCTION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL STIMULATION; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; HUMAN; HUMAN CELL; HUVEC CELL LINE; IC50; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; TUBE FORMATION; CELL CULTURE; CELL JUNCTION; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADHERENS JUNCTIONS; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; ASPIRIN; CADHERINS; CATENINS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NADPH OXIDASE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; SALICYLATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855600475     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834eecdc     Document Type: Article

References (28)

1. Herrmann J, Lerman LO, Mukhopadhyay D, et al. Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol 2006; 26:1948–1957.
2. Dass CR, Choong PF. Cancer angiogenesis: targeting the heel of Achilles. J Drug Target 2008; 6:449–454.
3. Vestweber D, Winderlich M, Cagna G, Nottebaum AF. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 2009; 19:8–15.
4. Antithrombotic Trialists’ Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849–1860.
5. Cuzick J, Otto F, Baron JA, et al. Aspirin and nonsteroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10:501–517.
6. Wu KK, Liou JY, Cieslik K. Transcriptional Control of COX-2 via C/EBPß. Arterioscler Thromb Vasc Biol 2005; 25:679–685.
7. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110:255–258.
8. Gilroy DW, Perretti M. Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr Opin Pharmacol 2005; 5:405–411.
9. Borthwick GM, Johnson AS, Partington M, et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006; 12:2009–2016.
10. Kapitanović S, Cacev T, Antica M, et al. Effect of indomethacin on E-cadherin and beta-catenin expression in HT-29 colon cancer cells. Exp Mol Pathol 2006; 80:91–96.
11. Yoshida J, Horiuchi A, Kikuchi N, et al. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol 2009; 42:82–91.
12. Lopez D, Niu G, Huber P, Carter WB. Tumor-induced upregulation of Twist, Snail, and Slug represses the activity of the human VE-cadherin promoter. Arch Biochem Biophys 2009; 482:77–82.
13. Rainstord KD. Side-effects and toxicology of the salicylates. In Rainsford KD, editor. Aspirin and the salicylates. London: Butterworths; 1984. pp. 148–220.
14. Gerrah R, Fogel M, Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol 2004; 94:25–29.
15. Grépin R, Pagès G. The Vascular Endothelial Growth Factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target? J Soc Biol 2009; 203:181–192.
16. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98:2108–2116.
17. Cai J, Jiang WG, Mansel RE. Phosphorylation and disorganization of vascular-endothelial cadherin in interaction between breast cancer and vascular endothelial cells. Int J Mol Med 1999; 4:191–195.
18. Pearce HR, Kalia N, Bardhan KD, Brown NJ. Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 2003; 18:1180–1187.
19. Osher E, Weisinger G, Limor R, et al. The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol 2006; 252:201–206.
20. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2006; 25:122–129.
21. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18:7908–7916.
22. Schönbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155:1281–1291.
23. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the betaarrest-independent endocytosis of VEcadherin. Nat Cell Biol 2006; 8:1223–1234.
24. Clarkin CE, Emery RJ, Pitsillides AA, Wheeler-Jones CP. Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol 2006; 214:537–544.
25. Wu G, Mannam AP, Wu J, et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol 2003; 285:H2420–H2429.
26. Wu G, Luo J, Rana JS, et al. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 2006; 69:512–519.
27. Maraldi T, Prata C, Caliceti C, et al. VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis. Int J Oncol 2010; 36:1581–1589.
28. Zhuang J, Jiang T, Lu D, et al. NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction. Free Radic Biol Med 2010; 49:227–236.